Controversies in the natural history of congenital human cytomegalovirus infection: the paradox of infection and disease in offspring of women with immunity prior to pregnancy

Medical Microbiology and Immunology

Volumn 204, Issue 3, 2015, Pages 263-271

  Britt, William ^a  

^a UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

Author keywords

CMV; Congenital CMV; Maternal immunity

Indexed keywords

CYTOMEGALOVIRUS VACCINE;

CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOMEGALOVIRUS INFECTION; DISEASE CLASSIFICATION; FEMALE; HUMAN; IMMUNITY; LETTER; MATERNAL DISEASE; NONHUMAN; OUTCOME ASSESSMENT; PREGNANCY; PREVALENCE; PRIORITY JOURNAL; PROGENY; PROTECTION; SEROPREVALENCE; TREPONEMA PALLIDUM; VIRUS TRANSMISSION; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; ENVIRONMENTAL EXPOSURE; IMMUNOLOGY; PHYSIOLOGY; PREGNANCY COMPLICATION; TRANSMISSION; VERTICAL TRANSMISSION;

CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; CYTOMEGALOVIRUS VACCINES; FEMALE; HUMANS; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MATERNAL EXPOSURE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; SEROEPIDEMIOLOGIC STUDIES;

EID: 84929965972     PISSN: 03008584     EISSN: 14321831     Source Type: Journal    
DOI: 10.1007/s00430-015-0399-9     Document Type: Letter

References (69)

1. Kenneson A, Cannon MJ (2007) Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection. Rev Med Virol 17:253–276
2. Britt WJ (2010) Cytomegalovirus. In: Remington JS, Klein JO, Wilson CB, Nizet V, Maldonaldo Y (eds) Infectious diseases of the fetus and newborn infant, 7th edn. Elsevier Saunders, Philadelphia, pp 706–755
3. Manicklal S, Emery VC, Lazzarotto T, Boppana SB, Gupta RK (2013) The “silent” global burden of congenital cytomegalovirus. Clin Microbiol Rev 26:86–102
4. Mussi-Pinhata MM, Yamamoto AY, Moura-Britto RM, Lima- Issacs M, Boppana S et al (2009) Birth prevalence and natural history of congenital cytomegalovirus (CMV) infection in highly seroimmune population. Clin Infect Dis 49:522–528
5. Boppana S, Fowler KB (2007) Persistence in the population:epidemiology and transmission. In: Arvin AC-FG, Mocarski E, Roizman B, Whitley R, Yamanishi K (eds) Human herpesviruses: biology, therapy, and immunoprophylaxis. Cambridge, Cambridge, UK, pp 795–813
6. Boppana SB, Ross SA, Fowler KB (2013) Congenital cytomegalovirus infection: clinical outcome. Clin Infect Dis 57(Suppl 4):S178–S181
7. (2000) Vaccines for the 21st century: a tool for decisionmaking. In: Stratton KR, Durch JS, Lawrence RS (eds) 2000 by the National Academy of Sciences, Washington, DC
8. Krause PR, Bialek SR, Boppana SB, Griffiths PD, Laughlin CA et al (2013) Priorities for CMV vaccine development. Vaccine 32:4–10
9. Plotkin SA, Friedman HM, Fleisher GR, Dafoe DC, Grossman RA et al (1984) Towne-vaccine induced prevention of cytomegalovirus disease after renal transplants. Lancet 1:528–530
10. Pass RF, Zhang C, Evans A, Simpson T, Andrews W et al (2009) Vaccine prevention of maternal cytomegalovirus infection. N Engl J Med 360:1191–1199
11. Stagno S, Pass RF, Dworsky ME, Henderson RE, Moore EG et al (1982) Congenital cytomegalovirus infection: the relative importance of primary and recurrent maternal infection. N Engl J Med 306:945–949
12. Ahlfors K, Harris S, Ivarsson S, Svanberg L (1981) Secondary maternal cytomegalovirus infection causing symptomatic congenital infection. N Engl J Med 305:284
13. Stagno S, Reynolds DW, Huang E-S, Thames SD, Smith RJ et al (1977) Congenital cytomegalovirus infection: occurrence in an immune population. N Engl J Med 296:1254–1258
14. Wang C, Zhang X, Bialek S, Cannon MJ (2011) Attribution of congenital cytomegalovirus infection to primary versus non-primary maternal infection. Clin Infect Dis 52:e11–e13
15. Townsend CL, Forsgren M, Ahlfors K, Ivarsson SA, Tookey PA et al (2013) Long-term outcomes of congenital cytomegalovirus infection in Sweden and the United Kingdom. Clin Infect Dis 56:1232–1239
16. Ahlfors K, Ivarsson SA, Harris S (2001) Secondary maternal cytomegalovirus infection—A significant cause of congenital disease. Pediatrics 107:1227–1228
17. Boppana SB, Fowler KB, Britt WJ, Stagno S, Pass RF (1999) Symptomatic congenital cytomegalovirus infection in infants born to mothers with preexisting immunity to cytomegalovirus. Pediatrics 104:55–60
18. Alford CA, Stagno S, Pass RF (1980) Natural history of perinatal cytomegalovirus infection. Perinatal Infections. Excerpta Medica, Amsterdam, pp 125–147
19. Alford CA, Stagno S, Pass RF, Huang ES (1981) Epidemiology of cytomegalovirus. In: Nahmais A, Dowdle W, Schinazi R (eds) The human herpesviruses: an interdisciplinary perspective. Elsevier, New York, pp 159–171
20. Boppana SB, Rivera LB, Fowler KB, Mach M, Britt WJ (2001) Intrauterine transmission of cytomegalovirus to infants of women with preconceptional immunity. N Engl J Med 344:1366–1371
21. Ross SA, Arora N, Novak Z, Fowler KB, Britt WJ et al (2009) Cytomegalovirus reinfections in healthy seroimmune women. J Infect Dis 201:386–389
22. Yamamoto AY, Mussi-Pinhata MM, Boppana SB, Novak Z, Wagatsuma VM et al (2010) Human cytomegalovirus reinfection is associated with intrauterine transmission in a highly cytomegalovirus-immune maternal population. Am J Obstet Gynecol 202:297.e291–297.e298
23. Enders G, Daiminger A, Bader U, Exler S, Enders M (2011) Intrauterine transmission and clinical outcome of 248 pregnancies with primary cytomegalovirus infection in relation to gestational age. J Clin Virol 52:244–246
24. Stagno S, Pass RF, Cloud G, Britt WJ, Henderson RE et al (1986) Primary cytomegalovirus infection in pregnancy. Incidence, transmission to fetus, and clinical outcome. JAMA 256:1904–1908
25. Pass RF, Stagno S, Myers GJ, Alford CA (1980) Outcome of symptomatic congenital CMV infection: results of long-term longitudinal follow-up. Pediatrics 66:758–762
26. Boppana SB, Pass RF, Britt WJ, Stagno S, Alford CA (1992) Symptomatic congenital cytomegalovirus infection: neonatal morbidity and mortality. Pediatr Infect Dis J 11:93–99
27. Boppana SB, Fowler KB, Vaid Y, Hedlund G, Stagno S et al (1997) Neuroradiographic findings in the newborn period and long-term outcome in children with symptomatic congenital cytomegalovirus infection. Pediatrics 99:409–414
28. Anderson KS, Amos CS, Boppana S, Pass R (1996) Ocular abnormalities in congenital cytomegalovirus infection. J Am Optom Assoc 67:273–278
29. Stagno S, Whitley RJ (1985) Herpesvirus infections of pregnancy. Part I: cytomegalovirus and Epstein-Barr virus infections. N Engl J Med 313:1270–1274
30. Dreher AM, Arora N, Fowler KB, Novak Z, Britt WJ et al (2014) Spectrum of disease and outcome in children with symptomatic congenital cytomegalovirus infection. J Pediatr 164:855–859
31. Hyde TB, Schmid DS, Cannon MJ (2010) Cytomegalovirus seroconversion rates and risk factors: implications for congenital CMV. Rev Med Virol 20:311–326
32. Revello MG, Lazzarotto T, Guerra B, Spinillo A, Ferrazzi E et al (2014) A randomized trial of hyperimmune globulin to prevent congenital cytomegalovirus. N Engl J Med 370:1316–1326
33. Fowler KB, Stagno S, Pass RF, Britt WJ, Boll TJ et al (1992) The outcome of congenital cytomegalovirus infection in relation to maternal antibody status. N Engl J Med 326:663–667
34. Ross SA, Fowler KB, Guha A, Stagno S, Britt WJ et al (2006) Hearing loss in children with congential cytomegalovirus infection born to mothers with preexisting immunity. J Pediatr 148:332–336
35. Yamamoto AY, Mussi-Pinhata MM, Isaac MDL, Amaral FR, Carvalheiro CG et al (2011) Congenital cytomegalovirus infection as a cause of sensorineural hearing loss in a highly seropositive population. Pediatr Infect Dis J 30:1043–1046
36. Dar L, Pati SK, Patro AR, Deorari AK, Rai S et al (2008) Congenital cytomegalovirus infection in a highly seropositive semi-urban population in India. Pediatr Infect Dis J 27:841–843
37. Gaytant MA, Steegers EA, Semmekrot BA, Merkus HM, Galama JM (2002) Congenital cytomegalovirus infection: review of the epidemiology and outcome. Obstet Gynecol Surv 57:245–256
38. Schopfer K, Lauber E, Krech U (1978) Congenital cytomegalovirus infection in newborn infants of mothers infected before pregnancy. Arch Dis Child 53:536–539
39. Kaye S, Miles D, Antoine P, Burny W, Ojuola B et al (2008) Virological and immunological correlates of mother-to-child transmission of cytomegalovirus in The Gambia. J Infect Dis 197:1307–1314
40. Bello C, Whittle H (1991) Cytomegalovirus infection in Gambian mothers and their babies. J Clin Pathol 44:366–369
41. Stagno S, Pass RF, Dworsky ME, Alford CA (1983) Congenital and perinatal cytomegaloviral infections. Semin Perinatol 7:31–42
42. de Vries JJ, van Zwet EW, Dekker FW, Kroes AC, Verkerk PH et al (2013) The apparent paradox of maternal seropositivity as a risk factor for congenital cytomegalovirus infection: a population-based prediction model. Rev Med Virol 23:241–249
43. Campos FA, de Andrade GM, de Padua Santos Lanna A, Lage BF, Assumpcao MV et al (2014) Incidence of congenital toxoplasmosis among infants born to HIV-coinfected mothers: case series and literature review. Braz J Infect Dis 18:609–617
44. Mitchell CD, Erlich SS, Mastrucci MT, Hutto SC, Parks WP et al (1990) Congenital toxoplasmosis occurring in infants perinatally infected with human immunodeficiency virus 1. Pediatr Infect Dis J 9:512–518
45. Kimberlin DW (2004) Neonatal herpes simplex infection. Clin Microbiol Rev 17:1–13
46. Pinninti SG, Kimberlin DW (2013) Maternal and neonatal herpes simplex virus infections. Am J Perinatol 30:113–119
47. Cooper LZ, Preblud SR, Alford CA (1995) Rubella. In: Remington JS, Klein JO (eds) Infectious diseases of the fetus and newborn infant, 4th edn. WB Saunders, Philadelphia, pp 268–311
48. (1994) Rubella and congenital rubella syndrome—United States, 1 Jan 1991–7 May 1994. MMWR 43:391–401
49. Cutts FT, Vynnycky E (1999) Modelling the incidence of congenital rubella syndrome in developing countries. Int J Epidemiol 28:1176–1184
50. (2010) Congenital syphilis—United States, 2003–2008. MMWR Morb Mortal Wkly Rep 59:413–417
51. Lafond RE, Lukehart SA (2006) Biological basis for syphilis. Clin Microbiol Rev 19:29–49
52. LaFond RE, Centurion-Lara A, Godornes C, Rompalo AM, Van Voorhis WC et al (2003) Sequence diversity of Treponema pallidum subsp. pallidum TprK in human syphilis lesions and rabbit-propagated isolates. J Bacteriol 185:6262–6268
53. LaFond RE, Molini BJ, Van Voorhis WC, Lukehart SA (2006) Antigenic variation of TprK V regions abrogates specific antibody binding in syphilis. Infect Immun 74:6244–6251
54. Britt WJ (1991) Recent advances in the identification of significant human cytomegalovirus-encoded proteins. Transplant Proc 23:64–69
55. Pati SK, Novak Z, Purser M, Arora N, Mach M et al (2012) Strain-specific neutralizing antibody responses against human cytomegalovirus envelope glycoprotein N. Clin Vaccine Immunol 19:909–913
56. Burkhardt C, Himmelein S, Britt W, Winkler T, Mach M (2009) Glycoprotein N subtypes of human cytomegalovirus induce a strain-specific antibody response during natural infection. J Gen Virol 90:1951–1961
57. Kropff B, Burkhardt C, Schott J, Nentwich J, Fisch T et al (2012) Glycoprotein N of human cytomegalovirus protects the virus from neutralizing antibodies. PLoS Pathog 8:e1002999
58. Jackson SE, Mason GM, Wills MR (2011) Human cytomegalovirus immunity and immune evasion. Virus Res 157:151–160
59. Powers C, Defilippis V, Malouli D, Frueh K (2008) Cytomegalovirus immune evasion. In: Shenk T, Stinski MF (eds) Human cytomegalovirus. Springer, Berlin-Heidelberg, pp 333–359
60. Lisnic VJ, Krmpotic A, Jonjic S (2010) Modulation of natural killer cell activity by viruses. Curr Opin Microbiol 13:530–539
61. Krmpotic A, Busch DH, Bubic I, Gebhardt F, Hengel H et al (2002) MCMV glycoprotein gp40 confers virus resistance to CD8+ T cells and NK cells in vivo. Nat Immunol 3:529–535 [see comment]
62. Babic M, Krmpotic A, Jonjic S (2011) All is fair in virus-host interactions: NK cells and cytomegalovirus. Trends Mol Med 17:677–685
63. Hansen SG, Powers CJ, Richards R, Ventura AB, Ford JC et al (2010) Evasion of CD8+ T cells is critical for superinfection by cytomegalovirus. Science 328:102–106
64. Hansen SG, Vieville C, Whizin N, Coyne-Johnson L, Siess DC et al (2009) Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat Med 15:293–299
65. Hansen SG, Ford JC, Lewis MS, Ventura AB, Hughes CM et al (2011) Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 473:523–527
66. Boppana SB, Britt WJ (1995) Antiviral antibody responses and intrauterine transmission after primary maternal cytomegalovirus infection. J Infect Dis 171:1115–1121
67. Furione M, Rognoni V, Sarasini A, Zavattoni M, Lilleri D et al (2013) Slow increase in IgG avidity correlates with prevention of human cytomegalovirus transmission to the fetus. J Med Virol 85:1960–1967
68. Lilleri D, Kabanova A, Revello MG, Percivalle E, Sarasini A et al (2013) Fetal human cytomegalovirus transmission correlates with delayed maternal antibodies to gH/gL/pUL128-130-131 complex during primary infection. PLoS One 8:e59863
69. Eberhardt MK, Deshpande A, Chang WL, Barthold SW, Walter MR et al (2013) Vaccination against a virus-encoded cytokine significantly restricts viral challenge. J Virol 87:11323–11331